| Literature DB >> 24040389 |
Lyle G Best1, Cindy M Anderson, Richa Saxena, Berta Almoguera, Hareesh Chandrupatla, Candelaria Martin, Gilbert Falcon, Kylie Keplin, Nichole Pearson, Brendan J Keating.
Abstract
BACKGROUND: The prevalence of variant alleles among single nucleotide polymorphisms (SNPs) is not well known for many minority populations. These population allele frequencies (PAFs) are necessary to guide genetic epidemiology studies and to understand the population specific contribution of these variants to disease risk. Large differences in PAF among certain functional groups of genes could also indicate possible selection pressure or founder effects of interest. The 50K SNP, custom genotyping microarray (CARe) was developed, focusing on about 2,000 candidate genes and pathways with demonstrated pathophysiologic influence on cardiovascular disease (CVD).Entities:
Mesh:
Year: 2013 PMID: 24040389 PMCID: PMC3765406 DOI: 10.1371/journal.pone.0075080
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1The proportion of PAFs in ranges for TMCC and HapMap populations.
Figure 2Plot of TMCC vs HapMap CEU PAFs.
Comparisons between TMCC and European PAFs reported in the literature.
| NHANES [4] vs TMCC | ||||||||
|---|---|---|---|---|---|---|---|---|
| PAF range | 0% | >0 = 20% | >20 = 40% | >40 = 60% | >60 = 80% | >80 = 100% | 100% | Total |
| Total SNPs | 1 | 3 | 1 | 10 | 14 | 9 | 0 | 38 |
| Differing | 0 | 1 | 1 | 7 | 12 | 7 | 0 | 28 |
| % of Total | 0.0 | 33.0 | 100.0 | 70.0 | 85.7 | 77.7 | 0.0 | 73.7 |
| Cross et al. [6] (European) vs TMCC | ||||||||
| Total SNPs | 0 | 1 | 4 | 11 | 8 | 3 | 0 | 27 |
| Differing | 0 | 1 | 2 | 9 | 6 | 3 | 0 | 21 |
| % of Total | 0.0 | 100.0 | 50.0 | 81.8 | 75.0 | 100.0 | 0.0 | 77.7 |
| Cross et al. [6] (American Indian) vs TMCC | ||||||||
| Total SNPs | 0 | 1 | 4 | 11 | 8 | 3 | 0 | 27 |
| Differing | 0 | 1 | 4 | 7 | 5 | 2 | 0 | 19 |
| % of Total | 0.0 | 100.0 | 100.0 | 63.6 | 62.5 | 66.6 | 0.0 | 70.3 |
| Huang et al. [5] vs TMCC | ||||||||
| Total SNPs | 0 | 2 | 3 | 5 | 13 | 4 | 0 | 27 |
| Differing | 0 | 2 | 2 | 5 | 9 | 4 | 0 | 22 |
| % of Total | 0.0 | 100.0 | 66.6 | 100.0 | 69.2 | 100.0 | 0.0 | 81.5 |
| Huang et al vs Cross vs NHANES | ||||||||
| Total SNPs | 0 | 0 | 0 | 4 | 2 | 1 | 0 | 7 |
| Differing | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 4 |
| % of Total | 0.0 | 0.0 | 0.0 | 25.0 | 100.0 | 100.0 | 0.0 | 57.1 |
Note this last comparison is for any one of the 3 literature reports that differs from one of the others
Functional groups with significantly increased numbers of PAFs differing from HapMap CEU.
| GROUP | TOTAL SNPs | DIFFERING | DAVID GENES | PROBABILITY | DIRECTION |
|---|---|---|---|---|---|
| 2 | 70 | 38 | 12 | 0.0928 | MORE |
| 5 | 130 | 67 | 15 | 0.1353 | MORE |
| 6 | 100 | 49 | 12 | 0.3149 | MORE |
| 7 | 144 | 49 | 7 | 0.0010 | LESS |
| 8 | 834 | 378 | 93 | 0.1604 | LESS |
| 9 | 76 | 31 | 6 | 0.1618 | LESS |
| 10 | 84 | 45 | 9 | 0.0973 | MORE |
| 11 | 16 | 9 | 7 | 0.3140 | MORE |
| 12 | 40 | 17 | 5 | 0.3368 | LESS |
| 14 | 367 | 159 | 31 | 0.0810 | LESS |
| 15 | 65 | 27 | 6 | 0.2199 | LESS |
| 17 | 62 | 34 | 5 | 0.0889 | MORE |
| 18 | 49 | 25 | 6 | 0.2439 | MORE |
| 19 | 145 | 65 | 12 | 0.3215 | LESS |
| 20 | 94 | 40 | 7 | 0.2181 | LESS |
| 21 | 105 | 38 | 5 | 0.0156 | LESS |
| 22 | 50 | 24 | 9 | 0.3931 | MORE |
| 23 | 91 | 36 | 6 | 0.0904 | LESS |
| 24 | 72 | 40 | 5 | 0.0600 | MORE |
| 25 | 107 | 48 | 13 | 0.3574 | LESS |
| 26 | 50 | 20 | 8 | 0.1941 | LESS |
| 27 | 84 | 43 | 12 | 0.1947 | MORE |
| 28 | 18 | 14 | 5 | 0.0018 | MORE |
| 29 | 343 | 147 | 15 | 0.0640 | LESS |
| 30 | 551 | 254 | 18 | 0.3344 | MORE |
| 31 | 75 | 32 | 5 | 0.2573 | MORE |
| 32 | 551 | 266 | 27 | 0.2756 | MORE |
| 33 | 628 | 301 | 62 | 0.3238 | MORE |
| 34 | 334 | 172 | 25 | 0.0481 | MORE |
| 35 | 143 | 82 | 10 | 0.0056 | MORE |
| 36 | 31 | 20 | 6 | 0.0166 | MORE |
| 37 | 25 | 10 | 11 | 0.3062 | LESS |
| 39 | 93 | 46 | 13 | 0.2873 | MORE |
| 40 | 423 | 184 | 10 | 0.0754 | LESS |
| 41 | 60 | 30 | 5 | 0.2808 | MORE |
| 42 | 71 | 37 | 6 | 0.1672 | MORE |
| 44 | 32 | 17 | 8 | 0.1949 | MORE |
| 46 | 83 | 34 | 9 | 0.1562 | LESS |
| 47 | 104 | 40 | 23 | 0.0472 | LESS |
| 49 | 16 | 8 | 6 | 0.3140 | LESS |
| 50 | 37 | 21 | 6 | 0.0899 | MORE |
| 52 | 99 | 42 | 32 | 0.2031 | LESS |
| 53 | 41 | 14 | 5 | 0.0651 | LESS |
Limited to those 43 with probability less than 0.35 of 53 groups in total.
Probability of this number (or more extreme comparisons) of SNP PAFs “Differing” out of the total, given an “a priori” probability of 0.471 for a “Differing” SNP PAF.
MORE indicates an excess of PAFs differing between the populations and LESS means there was a relative deficit of PAFs differing between the populations.
Characteristics of 7 Gene Groups showing significantly more or less SNPs with differing prevalences.
| Group 7 (collagen), p=0.0010 LESS | |||||
|---|---|---|---|---|---|
| COL6A2 | COL4A5 | COL9A2 | COL4A2 | COL4A1 | COL4A6 |
| Group 28 (insulin regulation, IGF1R), p=0.0018 MORE | |||||
| EIF2B1 | EIF2B3 | EIF2B4 | EIF2B5 | EIF2B2 | |
| Group 35 (immune response, T-cell signaling), p=0.0056 MORE | |||||
| NFATC4 | REL | TFAP2B | NFATC3 | NFATC1 | SOX5 |
| NFAT5 | NFATC2 | FOXJ2 | NFE2L2 | ||
| Group 21 (collagen), p=0.0156, LESS | |||||
| COL3A1 | COL1A2 | COL1A1 | COL5A2 | COL5A1 | |
| Group 36 (dual specificity phosphatase, Erk/JNK pathway), p=0.0166, MORE | |||||
| DUSP9 | DUSP7 | DUSP10 | DUSP5 | DUSP6 | DUSP2 |
| Group 47 (transmembrane proteins, Kell blood group), p=0.0472, LESS | |||||
| TSPAN31 | TMEM61 | TMEM132E | TMEM63A | CD53 | PRRT1 |
| ARMC10 | SMCR7 | TMEM132D | MS4A6A | PDZK1IP1 | C10orf72 |
| MUSTN1 | STARD3NL | ARV1 | C12orf23 | C14orf101 | C14orf118 |
| HAS3 | EVC | XKR6 | KIAA2013 | CCDC109B | |
| Group 34 (cytochrome P450, drug metabolism), p=0.0481, MORE | |||||
| CYP4A11 | CYP27A1 | CYP2D6 | CYP2E1 | CYP2C9 | TBXAS1 |
| CYP3A4 | CYP8B1 | CYP7A1 | CYP2J2 | CYP4F2 | CYP1A2 |
| CYP2C19 | CYP26A1 | CYP7B1 | CYP17A1 | CYP2A6 | CYP4B1 |
| CYP3A5 | CYP19A1 | CYP1B1 | CYP2A7 | CYP2C18 | CYP2C8 |